Interní Med. 2007; 9(5): 213-216

The development of bacterial resistance and new antimicrobial agents

doc. MUDr. Milan Kolář PhD
Ústav mikrobiologie FN a LF UP v Olomouci

Application of antibiotics is an important part of antibacterial therapy that can be simply understood as „nonphysiological interaction between bacteria and humans“. The increase of resistance against antimicrobial agents belongs to essential properties of bacteria. Because of this reason very important side effects are development and spreading of bacterial resistance that can be associated with increased morbidity and mortality of infections caused by multiresistant bacteria. This problem has to be solved on all appropriate levels, mainly by increased effort in development of new antibiotics and in the same time by thorough prevention of development and spreading of multiresistant bacteria in human population. The presented paper discusses directions of future development of new antibiotics and selected agents.

Keywords: bacterial resistance, new antibiotics

Published: June 21, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář M. The development of bacterial resistance and new antimicrobial agents. Interní Med. 2007;9(5):213-216.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aarestrup FM. Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals. Int. J Antimicrob Agents 1999; 12: 279-285. Go to original source... Go to PubMed...
    2. Bager F, Madsen M, Christensen J, Aarestrup FM. Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev Vet Med 1997; 31: 95-112. Go to original source... Go to PubMed...
    3. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the national nosocomial resistance surveillance group. Diag Microbiol Dis 1992; 15: 37-42. Go to original source...
    4. Bardoň J, Kolář M, Vágnerová I, Koukalová D, Čekanová L. Záchyt methicilin-rezistentního kmene Staphylococcus aureus u selat. Veterinářství 2006; 56: 622-629.
    5. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-59. Go to original source... Go to PubMed...
    6. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents 2006; 27: 476-481. Go to original source... Go to PubMed...
    7. Haley RW, Culver DH, White JW, et al. The nationwide nosocomial infection rate. A new need for vital statistics. Am J Epidemiol 1985; 121: 159-167. Go to original source... Go to PubMed...
    8. Haley RW, Schaberg DR, Crossley KB, et al. Extra charges and prolongation of stay attributable to nosocomial infections: a prospective interhospital comparison. Am J Med 1981; 70: 51-58. Go to original source... Go to PubMed...
    9. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Resp Crit Care Med 2002; 165: 867-903. Go to original source... Go to PubMed...
    10. Klare I, Badstubner D, Konstabel C, et al. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from faecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microb Drug Resist 1999; 5: 45-52. Go to original source... Go to PubMed...
    11. Kolář M, Bardoň J, Sauer P, et al. Fluoroquinolone-resistant Escherichia coli and Proteus mirabilis in poultry of middle Moravia, Czech Republic. Acta Vet Brno 2005; 74: 249-253. Go to original source...
    12. Kolář M, Bardoň J, Vágnerová I, et al. Occurrence of vancomycin-resistant enterococci in hens in the central region of Moravia. Vet Med 2000; 45: 93-97.
    13. Kolář M, Urbánek K, Čekanová L. Podklady pro racionální antibiotickou léčbu komunitních bakteriálních infekcí. Klin Farm Farmac 2003; 17: 22-24.
    14. Kolář M, Urbánek K, Látal T. Antibiotic selection pressure and development of bacterial resistance. Intern J Antimicrob Agents 2001; 17: 357-363. Go to original source... Go to PubMed...
    15. Kolář M, Urbánek K, Vágnerová I, Koukalová D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Therap 2006; 31: 67-72. Go to original source... Go to PubMed...
    16. Kolář M, Vágnerová I, Látal T. Vliv selekčního tlaku antimikrobních preparátů na výskyt vankomycin-rezistentních enterokoků u pacientů s hematologickým onemocněním. Klin Mikrobiol Inf Lék 2001; 7: 230-234.
    17. Levy SB. The antibiotic paradox: How the misuse of antibiotics destroys their curative powers. 2nd ed. Cambridge, MA, Perseus Publishing, 2002. Go to original source...
    18. Medeiros AA. Evolution and dissemination of ?-lactamases accelerated by generations of ?-lactam antibiotics. Clin Inf Dis 1997; 24: 19-45. Go to original source... Go to PubMed...
    19. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of british patients with nosocomial infection and bacteremia. Clin Infect Dis 2003; 37: 1453-1460. Go to original source... Go to PubMed...
    20. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-1073. Go to original source... Go to PubMed...
    21. Saier MH Jr. Bacterial diversity and the evolution of differentiation. ASM News 2000; 66: 337-343.
    22. Shnayerson M, Plotkin MJ. The killers within. Boston, MA, Little, Brown and Co. 2002.
    23. Urbánek K, Kolář M, Čekanová L. Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin. Pharm World Science 2005; 27: 104-107. Go to original source... Go to PubMed...
    24. Urbánek K, Kolář M, Strojil J, et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Safety 2005; 14: 741-745. Go to original source... Go to PubMed...
    25. Urbášková P, et al. Předběžné výsledky surveillance rezistence tří nejčastějších bakteriálních původců respiračních infekcí k antibiotikům v České republice v roce 2000. Zprávy CEM 2001; 10: 117-118.
    26. Urbášková P, Jakubů V, et al. Rezistence k makrolidům u druhu Streptococcus pyogenes v České republice v období 1996-2003. Epidemiol Mikrobiol Imunol 2004; 53: 196-202.
    27. Urbášková P, Macková B, Jakubů V, et al. Surveillance antibiotické rezistence invazivních izolátů Staphylococcus aureus v rámci EARSS. Zprávy CEM 2006; 15: 200-203.
    28. Vergis EN, Shankar N, Chow JW, et al. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis 2002; 35: 570-575. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.